SUPN
Supernus Pharmaceuticals, Inc. NASDAQ$48.63
Mkt Cap $2.8B
52w Low $29.16
63.8% of range
52w High $59.68
50d MA $51.09
200d MA $47.69
P/E (TTM)
-70.4x
EV/EBITDA
66.3x
P/B
2.5x
Debt/Equity
0.0x
ROE
-3.6%
P/FCF
61.0x
RSI (14)
—
ATR (14)
—
Beta
0.73
50d MA
$51.09
200d MA
$47.69
Avg Volume
691.5K
About
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an ext…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | AMC | 0.28 | 0.92 | +228.6% | 53.30 | +6.0% | +5.7% | +4.6% | +2.7% | +3.4% | +2.4% | — |
| Nov 4, 2025 | AMC | 0.82 | 1.01 | +23.2% | 57.00 | -21.6% | -17.4% | -17.1% | -19.3% | -20.4% | -19.1% | — |
| Aug 5, 2025 | AMC | 0.47 | 0.91 | +93.6% | 37.53 | +4.3% | +13.1% | +10.5% | +9.9% | +8.1% | +9.9% | — |
| May 6, 2025 | AMC | 0.38 | 0.42 | +10.5% | 32.43 | -7.4% | -4.6% | -2.7% | -2.3% | -0.9% | -0.5% | — |
| Feb 25, 2025 | AMC | 0.46 | 0.75 | +63.0% | 32.81 | +2.4% | -2.7% | -3.2% | -2.3% | -3.3% | -3.5% | — |
| Nov 4, 2024 | AMC | 0.39 | 1.06 | +171.8% | 34.70 | +13.5% | +0.1% | +8.8% | +4.9% | +5.5% | +5.5% | — |
| Aug 6, 2024 | AMC | 0.31 | 0.36 | +16.1% | 27.88 | +10.7% | +14.5% | +12.9% | +15.1% | +16.2% | +20.7% | — |
| May 8, 2024 | AMC | 0.38 | 0.26 | -31.6% | 31.30 | +0.7% | -4.2% | -7.5% | -5.2% | -7.4% | -8.2% | — |
| Feb 27, 2024 | AMC | 0.41 | 0.02 | -95.1% | 30.69 | -6.9% | +1.3% | -3.2% | +1.0% | -0.2% | -1.1% | — |
| Nov 8, 2023 | AMC | 0.13 | -0.29 | -323.1% | 23.52 | +6.3% | +11.1% | +13.3% | +16.2% | +19.2% | +21.6% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 19 | Stifel | Maintains | Hold → Hold | — | $49.28 | $48.90 | -0.8% | +4.5% | +4.5% | +4.9% | +5.1% | +4.6% |
| Oct 23 | TD Cowen | Maintains | Buy → Buy | — | $50.67 | $51.07 | +0.8% | +2.7% | +4.3% | +4.0% | +4.9% | +9.9% |
| Oct 9 | Piper Sandler | Upgrade | Neutral → Overweight | — | $48.00 | $51.08 | +6.4% | +3.1% | +2.1% | +0.8% | +2.5% | +2.6% |
| Sep 30 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $47.60 | $48.01 | +0.9% | +0.4% | +0.9% | +0.8% | +1.6% | +1.5% |
| Aug 29 | Piper Sandler | Maintains | Neutral → Neutral | — | $45.37 | $45.58 | +0.5% | -0.6% | -1.8% | -1.0% | +0.1% | +1.4% |
| Aug 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $37.53 | $39.15 | +4.3% | +13.1% | +10.5% | +9.9% | +8.1% | +9.9% |
| Feb 26 | Cantor Fitzgerald | Maintains | Neutral → Neutral | — | $32.81 | $33.59 | +2.4% | -2.7% | -3.2% | -2.3% | -3.3% | -3.5% |
| Feb 19 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $39.75 | $32.72 | -17.7% | -15.7% | -13.0% | -16.9% | -17.8% | -17.5% |
| Sep 11 | Piper Sandler | Downgrade | Overweight → Neutral | — | $33.49 | $32.71 | -2.3% | -7.2% | -7.7% | -7.1% | -6.0% | -5.3% |
| Feb 28 | Piper Sandler | Maintains | Overweight → Overweight | — | $30.69 | $28.58 | -6.9% | +1.3% | -3.2% | +1.0% | -0.2% | -1.1% |
Recent Filings
8-K
Supernus Pharmaceuticals, Inc. -- 8-K Filing
Supernus Pharmaceuticals will report Q1 2026 earnings on May 5, 2026, with management hosting a conference call at 4:30 p.m. ET for investor updates.
Apr 22
8-K · 5.02
!!! Very High
Alpha Cognition Inc. -- 8-K 5.02: Executive Change
Alpha Cognition Inc. (ACOG) appointed Bethany Sensenig as a director, expanding its board composition and potentially bringing new expertise to guide the company's strategic direction.
Apr 20
8-K · 2.01
!!! Very High
Unknown — 8-K 2.01: Acquisition Completed
SUPN completed a significant asset acquisition, potentially expanding its product portfolio or market reach and signaling management confidence in growth opportunities that could drive future revenue.
Apr 7
8-K · 5.02
!!! Very High
Supernus Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Supernus Pharmaceuticals modified executive compensation packages approved by its board, likely affecting future operating costs and management incentive alignment for investors tracking operational expenses.
Feb 24
8-K
Supernus Pharmaceuticals, Inc. -- 8-K Filing
I cannot provide a meaningful analysis based on this summary, as it contains only standard boilerplate forward-looking statement disclaimers without disclosing any specific business event, transaction, or material development affecting Supernus Pharmaceuticals investors.
Feb 24
8-K
Supernus Pharmaceuticals, Inc. -- 8-K Filing
Supernus Pharmaceuticals will report its 2025 financial results on February 24, 2026, followed by a management conference call at 4:30 p.m. ET.
Feb 12
8-K · 5.02
!!! Very High
Mitek Systems, Inc. -- 8-K 5.02: Executive Change
Mitek Systems appointed Eric Bell as Chief Accounting Officer, strengthening its accounting leadership team and potentially improving financial reporting oversight for investors.
Feb 5
Data updated apr 27, 2026 3:34am
· Source: massive.com